Skip to main content

Advertisement

Table 2 T/C% values and BWL% of the different treatments in the MNHOC124, MNHOC218 and MNHOC239 PDXs

From: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

  MNHOC124 MNHOC218 MNHOC239
  T/C% (day) BWL% (day) T/C% (day) BWL% (day) T/C% (day) BWL% (day)
PTX/BEV 5.4 (38) - 6.6 (46) 0.8 (31) 23.8 (64) -
PTX/MEK 55.5 (38) - 45.2 (46) 5.6 (38) 49.2 (61) 0.3 (28)
BEV/MEK 27.5 (38) 2.3 (31) 16.2 (16) 0.2 (38) 25.5 (61) -
PTX/BEV/MEK 5.5 (38) 1.3 (31) 0.7 (46) 4.7 (31) 13.7 (47) -
  1. T/C% values are considered significant of drug response when ≤42% (NCI guidelines). BWL: Body Weight Loss